In addition, ADAR1 can mediate A-to-I editing of miR-25-3p and miR-125a-3p binding sites in the 3’-UTR of dihydrofolate reductase (DHFR) and up-regulate the expression of DHFR, inducing cell proliferation and drug resistance in breast cancer [158]. This evidence concerns the gene DHFR and breast carcinoma.